title: Impact of single use versus reuse of cellulose dialyzers on clinical parameters and indices of biocompatibility.
abstract: Hemodialysis with reprocessed dialyzers has been associated with an increased mortality in patients on chronic dialysis, but the causes for this increased mortality have not been identified thus far. The aim of this study was to compare the qualitative and/or quantitative differences in activation of cellular and plasma elements, intradialytic signs and symptoms, adequacy of dialysis, and serum biochemistry and hematology in patients dialyzed with new or reprocessed cellulose dialyzers. This study measured the plasma levels and production of interleukin-1 receptor antagonist (IL-1Ra) by peripheral blood mononuclear cells (PBMC), indices of cytokine synthesis; plasma C3a levels, an index of complement activation; plasma levels of lipopolysaccharide binding protein (LBP), an acute phase reactant; and plasma levels of bactericidal-permeability increasing factor (BPI), a neutrophil primary granule protein, in 37 patients on chronic hemodialysis with glutaraldehyde and bleach-reprocessed cellulose dialyzers after random assignment to 12 wk of dialysis with new (single use) or reprocessed (reuse) cellulose dialyzers. These indices were studied before dialysis, 15 min after the start of dialysis, and at the conclusion of dialysis in both groups. Intradialytic clinical symptoms and signs, urea reduction ratios, monthly blood chemistry, and hematology were also studied during the 12-wk period. Before randomization, clinical and laboratory characteristics and IL-1Ra production by PBMC were similar in the two groups. During the 12-wk study, the mean number of dialyzer reuses was 7 +/- 1 in the reuse group and there were no breaks in protocol in the single-use group. At the end of the study, plasma levels of IL-1Ra, cell content and production of IL-1Ra by unstimulated, endotoxin-stimulated, and lgG-stimulated PBMC among patients assigned to reuse were not significantly different from those in the single-use group either before dialysis, at 15 min, or at the conclusion of dialysis. Similarly, plasma levels of C3a, LBP, and BPl were not significantly different between groups at any of the three time points. During the 12-wk study, none of the patients in either arm of the study experienced chills, rigors, or fever, and there were no differences in the number of episodes of symptomatic hypotension in patients on reused dialyzers (11 +/- 3) compared with patients on single-use dialyzers (8 +/- 2). The mean monthly urea reduction ratio during the 3 months of the study was 63 +/- 2% and 65 +/- 2% for reuse and single-use dialyzers, respectively (not significant). Similarly, the hematocrit, white blood cell count, serum calcium, phosphorus, cholesterol, triglycerides, total protein, and albumin levels were also not significantly different between the two groups at the end of the 12-wk study period. These results suggest that the reprocessing of cellulose dialyzers with glutaraldehyde and bleach does not affect indices of blocompatibility, intradialytic symptoms and signs, adequacy of dialysis, or serum biochemistry and hematology.
authors.affiliation: Division of Nephrology, New England Medical Center Hospital, Boston, MA 02111, USA.
authors.forename: B J
authors.initials: BJ
authors.lastname: Pereira
authors.forename: S N
authors.initials: SN
authors.lastname: Natov
authors.forename: S
authors.initials: S
authors.lastname: Sundaram
authors.forename: C H
authors.initials: CH
authors.lastname: Schmid
authors.forename: F R
authors.initials: FR
authors.lastname: Trabelsi
authors.forename: J A
authors.initials: JA
authors.lastname: Strom
authors.forename: A J
authors.initials: AJ
authors.lastname: King
mesh_terms: D000209:Acute-Phase Proteins; D000890:Anti-Infective Agents / Q000097:blood; D023181:Antimicrobial Cationic Peptides; D001672:Biocompatible Materials; D001769:Blood / Q000378:metabolism; D001798:Blood Proteins / Q000032:analysis; D002352:Carrier Proteins / Q000097:blood; D002482:Cellulose; D015331:Cohort Studies; D015926:Complement C3a / Q000032:analysis; D004209:Disposable Equipment; D006801:Humans; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D009000:Monocytes / Q000378:metabolism; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D017582:Renal Replacement Therapy / Q000295:instrumentation*; D000099231:Lipopolysaccharide-Binding Protein
chemical_list: D000209:Acute-Phase Proteins; D000890:Anti-Infective Agents; D023181:Antimicrobial Cationic Peptides; D001672:Biocompatible Materials; D001798:Blood Proteins; D002352:Carrier Proteins; D002482:Cellulose; D015926:Complement C3a; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D017472:Receptors, Interleukin-1; D000099231:Lipopolysaccharide-Binding Protein; C021623:bactericidal permeability increasing protein